Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 4Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 14Genitourinary 12Tumor-Agnostic 6Gynecologic 3Other hematologic neoplasm 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 6Neoplasm Metastasis 2

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasms × Prednisone × Tumor-Agnostic × Clear all
NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

Phase 1/2 Completed
175 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT03847649 2025-06-11

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Canadian Cancer Trials Group

Phase 2 Recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Astellas Pharma Inc

Phase 2 Completed
60 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT01637402 2020-08-17

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 2 Completed
41 enrolled 14 charts
Tumor-Agnostic

Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

AEterna Zentaris

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡